Or Eisenberg - Neurosense Therapeutics Chief Officer
| NRSN Stock | USD 0.86 0.07 7.53% |
Insider
Or Eisenberg is Chief Officer of Neurosense Therapeutics
| Age | 43 |
| Address | Building B, Herzliya, Israel, 4672562 |
| Phone | 972 9 799 6183 |
| Web | https://www.neurosense-tx.com |
Neurosense Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9484) %, meaning that it created substantial loss on money invested by shareholders. Neurosense Therapeutics' management efficiency ratios could be used to measure how well Neurosense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Neurosense Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 5.66, while Return On Tangible Assets are likely to drop (3.34). At this time, Neurosense Therapeutics' Total Assets are very stable compared to the past year. As of the 15th of December 2024, Net Tangible Assets is likely to grow to about 10.9 M, while Non Current Assets Total are likely to drop about 154 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD FACC | Longeveron LLC | 61 | |
| James CPA | Longeveron LLC | 58 | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| James Rolke | Revelation Biosciences | 55 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Ronald CPA | RenovoRx | N/A | |
| Angela Nelms | RenovoRx | 47 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Joan Brown | Allarity Therapeutics | 70 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| James Ahlers | RenovoRx | 60 | |
| Gerald Goodman | Nutriband | 76 | |
| Ramtin MD | RenovoRx | 58 | |
| James Foster | Virax Biolabs Group | 39 | |
| James JD | Allarity Therapeutics | 55 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 |
Neurosense Therapeutics Leadership Team
Elected by the shareholders, the Neurosense Therapeutics' board of directors comprises two types of representatives: Neurosense Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurosense. The board's role is to monitor Neurosense Therapeutics' management team and ensure that shareholders' interests are well served. Neurosense Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurosense Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharon Vered, Global CMC | ||
| Diana Shtossel, Head Affairs | ||
| Or Eisenberg, Chief Officer | ||
| Nedira SalzmanFrenkel, Global Devel | ||
| Yael Barak, Head Compliance | ||
| Alon BenNoon, CEO CoFounder | ||
| Hagit Binder, VP Operations | ||
| Ferenc MD, Chief Officer | ||
| Shiran Zimri, Head Program | ||
| Keren Pushett, Head HR | ||
| Eidan Loushi, CRA | ||
| Niva RussekBlum, Global Generator |
Neurosense Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurosense Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 | ||||
| Current Valuation | 18.72 M | ||||
| Shares Outstanding | 23.13 M | ||||
| Shares Owned By Insiders | 35.03 % | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 324.35 K | ||||
| Price To Book | 4.15 X | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (11.28 M) |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurosense Stock
Moving against Neurosense Stock
| 0.75 | DYAI | Dyadic International | PairCorr |
| 0.55 | ESPR | Esperion Therapeutics | PairCorr |
| 0.55 | BMY | Bristol Myers Squibb | PairCorr |
| 0.36 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.33 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.